The Efficacy of Regional Scalp Block in Craniotomy
Launched by UNIVERSITAS AIRLANGGA · Dec 5, 2024
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged \>18 years
- • American Society of Anesthesiologists (ASA) classification I-III
- • Glasgow Coma Scale (GCS) score ≥ 13
- • Elective craniotomy
- Exclusion Criteria:
- • - Patients with cardiovascular abnormalities, impaired renal and hepatic function, diabetes mellitus, systemic and/or scalp local infection, and those with a history of current dexamethasone administration
About Universitas Airlangga
Universitas Airlangga, a prestigious institution located in Surabaya, Indonesia, is dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its strong academic foundation and commitment to innovation to conduct rigorous and ethical clinical studies. With a focus on improving healthcare outcomes, Universitas Airlangga collaborates with various stakeholders, including healthcare professionals and industry partners, to explore new therapies and enhance patient care. Their research initiatives are aligned with global standards, ensuring the integrity and reliability of their findings in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Surabaya, Jawa Timur, Indonesia
Patients applied
Trial Officials
Christijogo Soemartono Waloejo, MD, Ph.D
Principal Investigator
Anesthesiology and Reanimation Department, Dr. Soetomo General Hospital, Universitas Airlangga, Indonesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported